Marizyme, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
November 22, 2021 at 08:58 pm
Share
Marizyme, Inc. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported sales was USD 0.037215 million compared to USD 0.124985 million a year ago. Net loss was USD 1.63 million compared to USD 2.07 million a year ago. Basic loss per share from continuing operations was USD 0.05 compared to USD 0.07 a year ago.
For the nine months, sales was USD 0.271952 million compared to USD 0.124985 million a year ago. Net loss was USD 5.48 million compared to USD 2.97 million a year ago. Basic loss per share from continuing operations was USD 0.15 compared to USD 0.13 a year ago.
Marizyme, Inc. is a medical technology company. The Company is focused on cardiac and surgical care by delivering innovative solutions for coronary artery bypass graft (CABG) surgery and other surgical procedures. Its product DuraGraft, is a one-time intraoperative vascular graft treatment for use in vascular and bypass surgeries that maintains endothelial function and structure, thereby reducing the incidence and complications of graft failure and improving clinical outcomes post bypass surgery. The Companyâs product under development includes MATLOC and MAR-FG-001. MATLOC is a lab-on-chip digital screening and diagnostic device platform being developed for quantitative chronic kidney disease (CKD) assessment. The MAR-FG-001 is a tumescent solution base for fat grafting procedures that is used for plastic and cosmetic surgeries in which fat is transferred from one area of the body to another to correct a defect, replace injured tissue, or to make cosmetic enhancements.